Methods of administering N -(5- tert -butyl-isoxazol-3-yl)-...

Details Methods of administering N -(5- tert -butyl-isoxazol-3-yl)-... Methods of administering N -(5- tert -butyl-isoxazol-3-yl)-...

2011-06-28

2011-06-28

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S360000, C514S380000

Reexamination Certificate

active

07968543

ABSTRACT:
Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Further, pharmaceutical formulations are provided. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.

REFERENCES:
patent: 2007/0232604 (2007-10-01), Bhagwat et al.
patent: WO 2007/109120 (2007-09-01), None
Gilliland et al., “The roles of FLT3 in hematopoiesis and leukemia,”Blood2002, vol. 100, pp. 1532-1542.
Stirewalt et al., “The role of FLT3 in haematopoietic malignancies,”Nat. Rev. Cancer2003, vol. 3, pp. 650-665.
Malempati et al., “Outcome after relapse among children with standard risk (SR) ALL treated on CCG-1952,”Blood(ASH Annual Annual Meeting Abstracts), 2004, vol. 104, Iss. 11, Abstract 520.
Levis et al., “FLT3 tyrosine kinase inhibitors,”Int .J. Hematol.2005, vol. 82, pp. 100-107.
Levis et al., “A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo,”Blood2002, vol. 99, pp. 3885-3891.
Kelly et al., “CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML),”Cancer Cell2002, vol. 1, pp. 421-432.
Weisberg et al., “Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412,”Cancer Cell2002, vol. 1, pp. 433-443.
Yee et al., “SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase,”Blood2002, vol. 100, pp. 2941-2949.
Whartenby et al., “Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease,”Proc. Natl. Acad. Sci. U.S.A.2005, vol. 102, pp. 16741-16746.
U.S. Appl. No. 60/994,635, filed Sep. 19, 2007, Bhagwat et al.
U.S. Appl. No. 12/233,906, filed Sep. 19, 2008, Bhagwat et al.

Affiliated with

Also associated with

Rating

Methods of administering N -(5- tert -butyl-isoxazol-3-yl)-... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of administering N -(5- tert -butyl-isoxazol-3-yl)-..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of administering N -(5- tert -butyl-isoxazol-3-yl)-... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2691249